3SBio Inc. Announces Unaudited First Quarter 2012 Results
SHENYANG, China, May 13, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the fir...
3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
SHENYANG, China, April 30, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has filed the Company's Annual Re...
3SBio Inc. Schedules Unaudited First Quarter 2012 Results
SHENYANG, China, April 23, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited first quarter 2012 resu...
3SBio Inc. Announces Changes to its Board of Directors
SHENYANG, China, March 21, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced changes to its board of directors (the "B...
3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2011 Results
SHENYANG, China, March 8, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the fo...
3SBio and DaVita Collaborate on Dialysis Clinics in Northeastern China
SHENYANG, China, March 8, 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio") a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration agreement with DaVita Inc. (NYSE: DVA), a le...
3SBio Inc. to Present at the Oppenheimer & Co. 6th Annual China Dragon Conference
SHENYANG, China, Feb. 7, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that Dr. Jing Lou, chief executive officer, and Mr...
3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2011 Results
SHENYANG, China, Feb. 3, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited fourth quarter ...
3SBio Inc. Announces Unaudited Third Quarter 2011 Results
SHENYANG, China, Nov. 10, 2011 /PRNewswire-Asia-FirstCall/ --* *3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial result...
3SBio Inc. Schedules Unaudited Third Quarter 2011 Results
SHENYANG, China,* *Oct. 20, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaud...
3SBio Inc. Announces Results of 2011 Annual General Meeting
SHENYANG, China, Sept. 21, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the results of shareholder votes at...
3SBio Inc. to Hold 2011 Annual General Meeting on September 20, 2011
SHENYANG, China, Aug. 20, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the annual general meeting of s...
3SBio Inc. Schedules Unaudited Second Quarter 2011 Results
SHENYANG, China, July 22, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudit...
3SBio Inc. Announces Unaudited First Quarter 2011 Results
Net revenues grew 22.7% year-on-year to RMB118.2 million (US$18.1 million) Reiterates 2011 net revenues guidance of US$76-US$82 million Submitted application to conduct clinical trials of voclosporin in China Seeking regulatory approval for EPIAO in selected PICS markets SHENYANG, Ch...
3SBio Inc. Schedules Unaudited First Quarter 2011 Results
SHENYANG, China, May 3, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its first qua...
3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2010 Results
2010 revenues grew 32.1% to RMB418.6 million (US$63.4 million) 2011 revenues expected to grow 20%-30% to US$76-US$82 million New GMP-certified plant to support domestic and international growth Secured new phase I and phase II compounds with significant unmet medical needs SHENYANG, China, M...
3SBio Inc. Schedules Unaudited Fourth Quarter and Fiscal Year 2010 Results
SHENYANG, China, Feb. 19, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited f...
3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
SHENYANG, China, Jan. 25, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or " Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has received official notif...
3SBio Inc. Acquires Worldwide Rights to Pegsiticase From EnzymeRx
SHENYANG, China, Nov. 29, 2010 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that is has acquired worldwide rights of pegsi...
